F
FidoCure
Committed to introducing the therapies that have been successfully used to treat humans with cancer into the world of veterinary medicine
About FidoCure
FidoCure operates in the veterinary healthcare market, focusing on providing advanced genetic testing and targeted therapies for canine cancer. The company serves veterinarians who are looking for innovative solutions to treat cancer in dogs. FidoCure's business model revolves around offering genetic sequencing and targeted therapy options, which veterinarians can use to prescribe personalized treatments for their canine patients. The company makes money by charging for its genetic testing services and the subsequent targeted therapies that are ordered based on the test results. FidoCure does not prescribe therapies directly but provides the necessary information for veterinarians to make informed decisions. This approach allows for the use of cutting-edge treatments that may not be widely available otherwise. The company aims to improve the quality of life for canine patients and provide new hope to pet owners by leveraging advanced medical technologies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Palo Alto, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 67.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Veterinary, Testing, Predictive Analytics, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, YC W18, medical testing
- Technology
- Big Data, Deep Tech
- Client focus
- b2c
- Investment activity
- 1 company, latest May 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning FidoCure.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Jul 2022 | $0 | — | Global Brain Corporation | — |
| OtherOther financing | Mar 2022 | $0 | — | Bossa Invest · Spark Growth Ventures | — |
Growth signals
Latest recorded traffic for FidoCure is 4.6K monthly website visits, up 15% over the last three months. FidoCure's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Y Combinator
BioAdvance
Rittenhouse Ventures
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Northeastern Pennsylvania
Andreessen Horowitz
Lerer Hippeau
Series A3 investors entered at this stage
Polaris Partners- BVBorealis Ventures
Tau Ventures
Other known investors8 additional known investors
Bossa Invest
Global Brain Corporation
Spark Growth Ventures
Civilization Ventures
For Good Ventures
Hem Suri
Nicholas Shekerdemian
World Solver Syndicate
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about FidoCure on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See FidoCure’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.